Evidence map›Paper›PMID 36589694›Full record

ArticleJournal of the American College of Clinical Pharmacy : JACCP2022

How to Implement a Pharmacogenetics Service at your Institution.

Emily J Cicali, Lauren Lemke, Hana Al Alshaykh, Khoa Nguyen, Larisa H Cavallari, Kristin Wiisanen

Abstract read
In one paragraph

Article in Journal of the American College of Clinical Pharmacy : JACCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emily J CicaliDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.
Lauren LemkeDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.
Hana Al AlshaykhDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.
Khoa NguyenDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.
Larisa H CavallariDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.
Kristin WiisanenDepartment of Pharmacotherapy and Translational Research, University of Florida, College of Pharmacy, Gainesville, FL, USA.

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M, JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Sparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
NCATS NIH HHS UL1 TR001427NHGRI NIH HHS U01 HG007269NHLBI NIH HHS U01 HL105198NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

The vast majority of patients possess one or more pharmacogenetic variants that can influence optimal medication use. When pharmacogenetic data are used to guide drug choice and dosing, evidence points to improved disease outcomes, fewer adverse effects, and lower healthcare spending. Although its science is well established, clinical use of pharmacogenetic data to guide drug therapy is still in its infancy. Pharmacogenetics essentially involves the intersection of an individual's genetic data with their medications, which makes pharmacists uniquely qualified to provide clinical support and education in this field. In fact, most pharmacogenetics implementations, to date, have been led by pharmacists as leaders or members of a multidisciplinary team or as individual practitioners. A successful large-scale pharmacogenetics implementation requires coordination and synergy among administrators, clinicians, informatics teams, laboratories, and patients. Because clinical implementation of pharmacogenetics is in its early stages, there is an urgent need for guidance and dissemination of shared experiences to provide a framework for clinicians. Many early adopters of pharmacogenetics have explored various strategies among diverse practice settings. This article relies on the experiences of early adopters to provide guidance for critical steps along the pathway to implementation, including strategies to engage stakeholders; evaluate pharmacogenetic evidence; coordinate laboratory testing, results interpretation and their integration into the electronic health record; identify reimbursement avenues; educate providers and patients; and maintain a successful program. Learning from early adopters' published experiences and strategies can allow clinicians leading a new pharmacogenetics implementation to avoid pitfalls and adapt and apply lessons learned by others to their own practice.

Indexed as

ImplementationPharmacogeneticsPharmacogenomicsPharmacy

Identifiers

PMID36589694
PMCPMC9799247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.